Tags : Blueprint

Weekly Snapshot

Weekly Snapshot (Jul 13- 17, 2020)

 1.  Eli Lilly Reports Results of Mirikizumab in P-III OASIS-2 Study to Treat Moderate to Severe Plaque Psoriasis Published: Jul 17, 2020 | Tags: Eli Lilly, Reports, Results, Mirikizumab, P-III, OASIS-2, Study, Treat, Moderate, Severe, Plaque Psoriasis 2.  Oncorus Initiates P-I Study of ONCR-177 in Patients with Advanced / Refractory Cutaneous Subcutaneous or Metastatic Nodal Solid […]Read More

Weekly Snapshot

Weekly Snapshot Jul 13- 17, 2020

 1.  Eli Lilly Reports Results of Mirikizumab in P-III OASIS-2 Study to Treat Moderate to Severe Plaque Psoriasis Published: Jul 17, 2020 | Tags: Eli Lilly, Reports, Results, Mirikizumab, P-III, OASIS-2, Study, Treat, Moderate, Severe, Plaque Psoriasis 2.  Oncorus Initiates P-I Study of ONCR-177 in Patients with Advanced / Refractory Cutaneous Subcutaneous or Metastatic Nodal Solid […]Read More

Pharma

Ipsen Signs Exclusive Worldwide License Agreement with Blueprint to Develop

Shots: Blueprint to receive $535M including $25M up front and up to $510M as development, regulatory & commercial milestone for BLU-782 in up to two indications, including FOP with royalties on global sales of BLU-782 The collaboration robust Ipsen’s rare diseases portfolio and accelerates Blueprint’s aim to globally develop BLU-782 by utilizing Ipsen’s clinical expertise […]Read More